Patients aged 12 years or older with pulmonary DS-TB may receive a 4-month regimen of isoniazid, rifapentine, moxifloxacin and pyrazinamide (2HPMZ/2HPM). (Conditional recommendation, moderate certainty of evidence) – new recommendation
In children and adolescents aged between 3 months and 16 years with non-severe TB (without suspicion or evidence of multidrug- or rifampicin- resistant TB [MDR/RR-TB]), a 4-month treatment regimen (2HRZ(E)/2HR) should be used. (Strong recommendation, moderate certainty of evidence) – new recommendation